Biotechnology Assets SA
MAD:BST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotechnology Assets SA
Net Income (Common)
Biotechnology Assets SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotechnology Assets SA
MAD:BST
|
Net Income (Common)
-€2.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Grifols SA
MAD:GRF
|
Net Income (Common)
€402m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Net Income (Common)
-€2.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-10%
|
|
|
Pharma Mar SA
MAD:PHM
|
Net Income (Common)
€75m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
28%
|
|
Biotechnology Assets SA
Glance View
Biotechnology Assets SA operates as a biopharmaceutical company. The company is headquartered in Jerez De La Frontera, Cadiz and currently employs 32 full-time employees. The company went IPO on 2011-06-14. The Firm’s main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.
See Also
What is Biotechnology Assets SA's Net Income (Common)?
Net Income (Common)
-2.1m
EUR
Based on the financial report for Jun 30, 2025, Biotechnology Assets SA's Net Income (Common) amounts to -2.1m EUR.
What is Biotechnology Assets SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
35%
Over the last year, the Net Income (Common) growth was 32%. The average annual Net Income (Common) growth rates for Biotechnology Assets SA have been 3% over the past three years , 35% over the past five years .
